Genocea Biosciences Inc. has closed a $35 million Series B round of venture financing that the company expects will take it deep into clinical development of its lead program, a therapeutic vaccine for herpes simplex virus type 2 (HSV-2) infections, and bring candidates for chlamydia, pneumonia, malaria and herpes prophylaxis in its pipeline up to the clinical stage.